Literature DB >> 24573957

Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.

Ruri Kikura-Hanajiri1, Nahoko Uchiyama Maiko Kawamura, Yukihiro Goda.   

Abstract

To counter the spread of the many analogues of psychoactive substances, the Pharmaceutical Affairs Law in Japan was amended in 2006 to establish a new category - Designated Substances - in order to more promptly control these drugs. As of March 2013, 106 substances (including one plant, Salvia divinorum) were listed in the category of Designated Substances, and 13 of them had had their category changed from Designated Substances into the much stricter category, Narcotics. However, new analogues of controlled substances, especially synthetic cannabinoids, appeared one-by-one since the new category was introduced. To avoid a cat-and-mouse game between regulators and illicit drug manufacturers, a comprehensive system (generic scheduling) for designating naphthoylindole-type synthetic cannabinoids, with particular substituents, was introduced into the Designated Substances in 2013. Since late 2012, the naphthoylindole-type compounds have been gradually replaced by other types of synthetic cannabinoids, such as cyclopropylmethanones, cannabimimetic carboxamide derivatives, adamanthoyl indoles, and cannabimimetic quinolinyl carboxylates. After the enforcement of the generic scheduling for designating naphthoylindoles in March 2013, these naphthoylindoles have been completely replaced by other types and have rarely been detected in the products. New types of psychoactive substances, including opioid receptor agonists (e.g. AH-7921, MT-45), hallucinogenic phenethylamines (e.g. NBOMe-type compounds), and thiophene derivatives (e.g. methiopropamine, α-PVT) have also appeared. The almost infinite possibilities of altered structures of chemicals make it difficult to carry out effective and exhaustive scheduling. To prevent the widespread distribution and abuse of these new psychoactive substances, continuous and dedicated monitoring for the emergence of these substances is necessary.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  generic scheduling; new psychoactive substances; synthetic cannabinoids

Mesh:

Substances:

Year:  2013        PMID: 24573957     DOI: 10.1002/dta.1584

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  12 in total

1.  The effect of banning MDPV on the incidence of MDPV-positive findings among users of illegal drugs and on court decisions in traffic cases in Finland.

Authors:  Pirkko Kriikku; Janne Rintatalo; Katja Pihlainen; Jukka Hurme; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2015-04-02       Impact factor: 2.686

2.  Locomotor activity and discriminative stimulus effects of a novel series of synthetic cathinone analogs in mice and rats.

Authors:  Michael B Gatch; Sean B Dolan; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2017-02-16       Impact factor: 4.530

Review 3.  Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication.

Authors:  Katharina Elisabeth Grafinger; Matthias E Liechti; Evangelia Liakoni
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

4.  A case of diffuse alveolar hemorrhage following synthetic cathinone inhalation.

Authors:  Masakazu Nitta; Taro Tamakawa; Natsuo Kamimura; Tadayuki Honda; Hiroshi Endoh
Journal:  World J Emerg Med       Date:  2020

5.  Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.

Authors:  Jakub Wojcieszak; Dariusz Andrzejczak; Agata Woldan-Tambor; Jolanta B Zawilska
Journal:  Neurotox Res       Date:  2016-06-13       Impact factor: 3.911

Review 6.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.

Authors:  Cristina Miliano; Giovanni Serpelloni; Claudia Rimondo; Maddalena Mereu; Matteo Marti; Maria Antonietta De Luca
Journal:  Front Neurosci       Date:  2016-04-19       Impact factor: 4.677

7.  High prevalence of quasi-legal psychoactive substance use among male patients in HIV care in Japan: a cross-sectional study.

Authors:  Kanna Hayashi; Chihiro Wakabayashi; Yuzuru Ikushima; Masayoshi Tarui
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-02-23

8.  A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N-OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products.

Authors:  Nahoko Uchiyama; Yoshihiko Shimokawa; Ruri Kikura-Hanajiri; Yosuke Demizu; Yukihiro Goda; Takashi Hakamatsuka
Journal:  Forensic Toxicol       Date:  2015-02-11       Impact factor: 4.096

9.  Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances.

Authors:  Zhenhua Qian; Zhendong Hua; Cuimei Liu; Wei Jia
Journal:  Forensic Toxicol       Date:  2015-11-13       Impact factor: 4.096

10.  The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities.

Authors:  Mitchell Longworth; Samuel D Banister; James B C Mack; Michelle Glass; Mark Connor; Michael Kassiou
Journal:  Forensic Toxicol       Date:  2016-04-27       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.